MSCV Citations (10)

Originally described in: miR-19 is a key oncogenic component of mir-17-92.
Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L Genes Dev. 2009 Dec 15. 23(24):2839-49. PubMed Journal

---

Articles Citing MSCV

Articles
Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca(2)(+)/calmodulin-dependent protein kinase II. Meng Z, Li T, Ma X, Wang X, Van Ness C, Gan Y, Zhou H, Tang J, Lou G, Wang Y, Wu J, Yen Y, Xu R, Huang W. Mol Cancer Ther. 2013 Oct;12(10):2067-77. doi: 10.1158/1535-7163.MCT-13-0314. Epub 2013 Aug 19. PubMed
Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells. Yoo BH, Khan IA, Koomson A, Gowda P, Sasazuki T, Shirasawa S, Gujar S, Rosen KV. Autophagy. 2018;14(1):134-151. doi: 10.1080/15548627.2017.1370171. Epub 2017 Dec 21. PubMed
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis. Du C, Hansen LJ, Singh SX, Wang F, Sun R, Moure CJ, Roso K, Greer PK, Yan H, He Y. Cell Rep. 2019 Sep 17;28(12):3199-3211.e5. doi: 10.1016/j.celrep.2019.08.031. PubMed
HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL. J Clin Invest. 2020 Apr 1;130(4):1635-1652. doi: 10.1172/JCI129497. PubMed
A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel. Baras A, Bocket L, Beauvais D, Hallaert C, Varlet P, Yakoub-Agha I, Hober D, Alidjinou EK. J Mol Diagn. 2021 Apr;23(4):447-454. doi: 10.1016/j.jmoldx.2020.12.004. Epub 2020 Dec 30. PubMed
ZNF768 links oncogenic RAS to cellular senescence. Villot R, Poirier A, Bakan I, Boulay K, Fernandez E, Devillers R, Gama-Braga L, Tribouillard L, Gagne A, Duchesne E, Caron D, Berube JS, Berube JC, Coulombe Y, Orain M, Gelinas Y, Gobeil S, Bosse Y, Masson JY, Elowe S, Bilodeau S, Manem V, Joubert P, Mallette FA, Laplante M. Nat Commun. 2021 Aug 17;12(1):4841. doi: 10.1038/s41467-021-24932-w. PubMed
Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization. Du C, Li SW, Singh SX, Roso K, Sun MA, Pirozzi CJ, Yang R, Li JL, He Y. Mol Cancer Res. 2021 Dec;19(12):2046-2056. doi: 10.1158/1541-7786.MCR-21-0093. Epub 2021 Sep 14. PubMed
EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Verma A, Singh A, Singh MP, Nengroo MA, Saini KK, Satrusal SR, Khan MA, Chaturvedi P, Sinha A, Meena S, Singh AK, Datta D. Nat Commun. 2022 Nov 29;13(1):7344. doi: 10.1038/s41467-022-35059-x. PubMed
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning. Estevam GO, Linossi EM, Rao J, Macdonald CB, Ravikumar A, Chrispens KM, Capra JA, Coyote-Maestas W, Pimentel H, Collisson EA, Jura N, Fraser JS. bioRxiv [Preprint]. 2024 Dec 5:2024.07.16.603579. doi: 10.1101/2024.07.16.603579. PubMed
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain. Estevam GO, Linossi EM, Macdonald CB, Espinoza CA, Michaud JM, Coyote-Maestas W, Collisson EA, Jura N, Fraser JS. Elife. 2024 Sep 13;12:RP91619. doi: 10.7554/eLife.91619. PubMed

If you have published an article using this material, please email us at to have your article added to this page.